Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma

Journal of Clinical Oncology

Volumn 25, Issue 11, 2007, Pages 1350-1356

  Rubenstein, James L ^a   Fridlyand, Jane ^b   Abrey, Lauren ^b   Shen, Arthur ^b   Karch, Jon ^b   Wang, Endi ^b   Issa, Samar ^b   Damon, Lloyd ^b   Prados, Michael ^b   McDermott, Michael ^b   O'Brien, Joan ^b   Haqq, Chris ^b   Shuman, Marc ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LABETALOL; PROTEIN KINASE; PROTEIN KINASE PIM 2; RITUXIMAB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ADULT; AGED; ARTICLE; BRAIN LYMPHOMA; CANCER STAGING; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DIPLOPIA; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; INTRAOCULAR TUMOR; LEUKOENCEPHALOPATHY; MALE; MONOTHERAPY; NAUSEA AND VOMITING; NONHODGKIN LYMPHOMA; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; TACHYPNEA; THORAX PAIN; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CENTRAL NERVOUS SYSTEM NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE NEOPLASMS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 34248173334     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.7311     Document Type: Article

References (25)

1. Van Besien K, Ha CS, Murphy S, et al: Risk factors, treatment and outcome of central nervous recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91:1178-1184, 1998
2. Rubenstein JL, Treseler P, O'Brien JM: Pathology and genetics of primary central nervous system and intraocular lymphoma. Hematol Oncol Clin North Am 19:705-717, 2005
3. Shah G, DeAngelis L: Treatment of primary central nervous system lymphoma. Hematol Oncol Clin North Am 19:611-627, 2005
4. Rubenstein JL, Combs D, Rosenberg J, et al: Rituximab in CNS lymphoma: Targeting the leptomeningeal compartment. Blood 101:466-468, 2003
5. Feugier P, Virion J, Tilly H, et al: Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: Influence of rituximab. Ann Oncol 15:129-133, 2004
6. Abrey LE, Batchelor TT, Ferreri AJ, et al: Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034-5043, 2005
7. Wiestner A, Rosenwald A, Barry TS, et al: ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101:4944-4951, 2003
8. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000
9. Wright G, Tan B, Rosenwald A, et al: A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 100:9991-9996, 2003
10. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al: DEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15:3266-3274, 1997
11. Dobson AT, Raja R, Abeyta MJ, et al: The unique transcriptome through day 3 of human pre-implantation development. Hum Mol Genet 13:1461-1470, 2004
12. Rubenstein J, Fridlyand J, Shen A, et al: Gene expression and angiotropism in primary CNS lymphoma. Blood 107:3716-3723, 2006
13. Ithaka R, Gentleman RR: A language for data analysis and graphics. J Comput Graph Stat 5:299-314, 1996
14. Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:1-26, 2004
15. Holm S: A simple sequentially rejective multiple test procedure. Scand J Statist 6:65-70, 1979
16. Rosenwald A, Wright G, Chan WC, et al: Lymphoma/leukemia molecular profiling project: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
17. Banham AH, Connors JM, Brown PJ, et al: Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 11:1065-1072, 2005
18. Barrans SL, Fenton JA, Banham A, et al: Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 104:2933-2935, 2004
19. Wright G, Tan B, Rosenwald A, et al: A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 100:9991-9996, 2003
20. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al: IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15:3266-3274, 1997
21. Fox CJ, Hammerman PS, Cinalli RM, et al: The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev 17:1841-1854, 2003
22. Hammerman PS, Fox CJ, Cinalli RM, et al: Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappa B activation. Cancer Res 64:8341-8348, 2004
23. Yan B, Zemskova M, Holder S, et al: The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem 278:45358-45367, 2003
24. Edwards JC, Szczepanski L, Szechinski J, et al: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572-2581, 2004
25. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002